An Anti‐PSMA Bivalent Immunotoxin Exhibits Specificity and Efficacy for Prostate Cancer Imaging and Therapy
Open Access
- 22 November 2012
- journal article
- research article
- Published by Wiley in Advanced Healthcare Materials
- Vol. 2 (5) , 736-744
Abstract
Prostate specific membrane antigen (PSMA) is overexpressed on prostate tumor cells and the neovascular endothelia various solid tumors. A bivalent immunotoxin generated by fusing a fold‐back single‐chain diabody derived from the Fv fragments of an anti‐PSMA monoclonal antibody with a truncated diphtheria toxin (DT) containing the activity and translocation domains [A‐dmDT390‐scfbDb(PSMA)] might be suitable for targeted therapy of tumors that overexpress PSMA. In this study, a PSMA‐positive and a PSMA‐negative prostate cancer cell lines were treated with immunotoxin A‐dmDT390‐scfbDb(PSMA) in order to study the tumor targeting specificity and therapeutic potential of the immunotoxin. The cellular uptake and selective toxicity of the immunotoxin were evident in monolayer cultures of PSMA‐positive LNCaP prostate cancer cells but not in cultures of PSMA‐negative PC‐3 prostate cancer cells. Cellular accumulation of A‐dmDT390‐scfbDb(PSMA) increased with increasing incubation times and concentrations in LNCaP cells. The proportion of apoptotic LNCaP cells increased upon incubation with increasing doses of the fold‐back immunotoxin. Optical imaging and MRI with the Alexa Fluor 680‐labeled A‐dmDT390‐scfbDb(PSMA) confirmed the specific targeting and therapeutic efficacy of this immunotoxin towards PSMA‐positive LNCaP solid tumor xenografts in athymic nude mice.Keywords
This publication has 31 references indexed in Scilit:
- Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single‐chain diabodyThe Prostate, 2010
- Saporin toxin‐conjugated monoclonal antibody targeting prostate‐specific membrane antigen has potent anticancer activityThe Prostate, 2010
- Prostate‐specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancerThe Prostate, 2009
- Construction and Preliminary Investigation of a Plasmid Containing a Novel Immunotoxin DT390-IL-18 Gene for the Prevention of Murine Experimental Autoimmune EncephalomyelitisDNA and Cell Biology, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- A fold-back single-chain diabody format enhances the bioactivity of an anti-monkey CD3 recombinant diphtheria toxin-based immunotoxinProtein Engineering, Design and Selection, 2007
- Improvement of a Recombinant Anti-Monkey Anti-CD3 Diphtheria Toxin Based Immunotoxin by Yeast Display Affinity Maturation of the scFvBioconjugate Chemistry, 2007
- Prevention of murine experimental autoimmune encephalomyelitis by in vivo expression of a novel recombinant immunotoxin DT390-RANTESGene Therapy, 2006
- Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigenExpert Opinion on Therapeutic Targets, 2005
- Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxelAnti-Cancer Drugs, 1998